Skip to main content

Table 3 Demographic and medical data

From: Inspiratory muscle strength training improves weaning outcome in failure to wean patients: a randomized trial

  IMST n= 35 SHAM n= 34 P value
   Age (years) 65.6 ± 11.7 65.1 ± 10.7 0.86
   Gender (male/female) 16/19 15/19 0.42
Number of smokers
Pack * years smoking history
12
54 ± 28
11
50 ± 30
0.86
0.72
Pre-albumin at study start
(mg/dL)
15.3 ± 6.6 15.4 ± 6.3 0.96
   MV support days to start of study intervention 41.9 ± 25.5 47.3 ± 33.0 0.36
Total MV support days from hospital admission until end
of study participation
57.3 ± 29.5 63.5 ± 34.0 0.46
   Total study days 14.4 ± 8.1 18.0 ± 8.8 0.10
   SAPS II at study start 33.5 ± 8.6 33.0 ± 8.6 0.83
Dynamic compliance    
(ml/cm H2O) n = 26 n = 27 aTr = 0.93
Pre-training 53.9 ± 18.3 53.8 ± 17.1 bTi = 0.19
Post-training 57.8 ± 19.5 57.1 ± 21.4 cTr × Ti = 0.91
Dynamic inspired airway resistance    
(cm H2O/L/S) n = 26 n = 27 aTr = 0.70
Pre-training 7.8 ± 3.2 7.1 ± 3.0 bTi = 0.12
Post-training 7.7 ± 1.8 8.8 ± 3.0 cTr × Ti = 0.08
Dynamic expired airway resistance    
(cm H2O/L/S) n = 26 n = 27 aTr = 0.74
Pre-training 8.1 ± 3.6 7.3 ± 3.1 bTi = 0.16
Post-training 7.9 ± 1.8 9.1 ± 3.4 cTr × Ti = 0.07
   Renal function    
Blood urea nitrogen
(mg/dL)
35.6 ± 15.6 37.6 ± 23.3 0.67
Creatinine (mg/dL)
(Includes subjects receiving renal replacement therapy)
1.1 ± 0.9 1.0 ± 0.7 0.74
Renal replacement therapy
n (%)
15 (43%) 10 (29%) 0.33
   Mean daily fluid balance (ml) 118 ± 964 405 ± 573 0.14
   Arterial blood gases on baseline MV support (initial day of study)    
   pH 7.41 ± 0.07 7.42 ± 0.06 0.68
   PaCO2 (torr) 42.9 ± 7.4 40.3 ± 10.0 0.20
PaO2 (torr) 113.8 ± 48.0 108.8 ± 33.0 0.60
   HCO3- (mEq/L) 27.2 ± 5.1 26.0 ± 2.9 0.30
   PaO2/FiO2 293 ± 125 278 ± 97 0.60
   MV settings (initial day of study)    
   SIMV (br/min) 4.5 ± 3.7 3.8 ± 2.2 0.37
   Pressure Support (cm H2O) 10.4 ± 1.8 10.0 ± 3.4 0.53
   PEEP (cm H2O) 5.4 ± 1.0 5.8 ± 1.6 0.27
   FiO2 0.40 ± 0.03 0.40 ± 0.004 0.77
   Study-related activity    
   Initial ATC trial duration to failure (hours) 2.5 ± 2.1 3.1 ± 3.1 0.39
   Number of study days patients were unable to participate 3.4 ± 5.0 3.8 ± 4.7 0.77
   (% of study days) (16 ± 21%) (15 ± 18%) 0.87
   Pressure setting on IMST device (cm H2O) Pre 7.2 ± 2.6 - < 0.0001
  Post 12.8 ± 3.6   
Pressure developed at tracheotomy tube during treatment (cmH2O)    aTr = 0.26
Pre-training -9.54 ± 3.70 -3.10 ± 1.54 bTi = 0.0003
Post-training -14.52 ± 4.59 -3.36 ± 2.08 cTr×Ti < 0.0001
  1. Data are mean ± standard deviation.
  2. ATC, aerosol tracheotomy collar; FiO2, fraction of inspired oxygen; HCO3-, arterial bicarbonate concentration; IMST, inspiratory muscle strength training; MV, mechanical ventilation; PaCO2, arterial pressure of carbon dioxide; PaO2, arterial pressure of oxygen; PaO2/FiO2, ratio of arterial pressure of oxygen to inspired oxygen fraction; PEEP, positive end expiratory pressure; SAPS II, new simplified acute physiology score; SIMV, synchronized intermittent mandatory ventilation.
  3. aTr, treatment factor, bTi, time factor, cTr × TI treatment × time interaction factor for two-way repeated measures analysis of variance on dynamic compliance, dynamic inspired airway resistance, dynamic expired airway resistance and pressure developed at tracheotomy tube during training variables. All other variables were tested with T tests for independent samples, paired samples or Chi-square tests.